What is Apogee Therapeutics, Inc.'s EBITDA?

Apogee Therapeutics, Inc. (APGE) reported EBITDA of -$82.36M in Q1 2026.

How has Apogee Therapeutics, Inc.'s EBITDA changed year-over-year?

Apogee Therapeutics, Inc.'s EBITDA decreased by 31.0% year-over-year, from -$62.89M to -$82.36M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Apogee Therapeutics, Inc. APGE EBITDA

EBITDA at other companies

Eli LillyLLY

——

Regeneron PharmaceuticalsREGN

——

AbbVieABBV

——

Protagonist TherapeuticsPTGX

——

Arrowhead ResearchARWR

——

IQVIAIQV

——

Other financials

Income statement

See full

Operating income-$82.8M-31.2%

Net income-$74.1M-33.9%

EPS (diluted)-$1.06-11.6%

Balance sheet

See full

Cash & equivalents$451.8M+323%

Total debt$8.0M-31.9%

Total assets$1.3B+81.1%

Cash flow

See full

Operating cash flow-$55.6M-14.6%

CapEx$62.0K—

Free cash flow-$62.8M+7.3%

Valuation

See full

Market cap$6.81B+189%

Enterprise value$6.37B+181%

Returns & leverage

See full

Current ratio32.6×+16.8×

Where this comes from

Calculated from Apogee Therapeutics, Inc.’s reported figures.

−$82.8Mebit+

$408.0KDepreciation Depletion & Amortization

=-$82.36M

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s EBITDA?: Apogee Therapeutics, Inc. (APGE) reported EBITDA of -$82.36M in Q1 2026.
How has Apogee Therapeutics, Inc.'s EBITDA changed year-over-year?: Apogee Therapeutics, Inc.'s EBITDA decreased by 31.0% year-over-year, from -$62.89M to -$82.36M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.